Effectiveness of raltegravir in combination with Atazanavir/Ritonavir and Lamivudine as secondline ART- A case report

Abstract

Increase in the number of people being initiated on Anti retroviral therapy, there is inevitably an increase in the number of people failing first-line therapy. The choice and rationale for selection of second-line therapy is limited. Constructing a second line regimen is a challenge for patients who have been exposed to all classes of NRTI’s in resource poor settings. The combination of Raltegravir with boosted atazanavir is a viable option if proved effective in trials with sufficient statistical power. We report a case of 48 week follow-up data of a patient started on Boosted atazanavir with Lamivudine and Raltegravir as secondline.